Gilligan B, Wodak J, Stark R, O'Halloran M
Med J Aust. 1979 Aug 25;2(4):205-7.
Twenty-seven patients with idiopathic Parkinson's disease completed a double-blind crossover trial which compared enteric-coated levodopa (Prodopa) with levodopa-carbidopa combination (Sinemet). It was easy to stabilize the patients' condition with either drug, and the dose-sparing effect both of the enteric-coated preparation, and of the levodopa-carbidopa combination was again noted. At the dosages used, the levodopa-carbidopa combination was objectively shown to be more effective in 71% of the patients investigated, although there was no clear personal preference for either preparation when patients compared the two parts of the trial. Both drugs play a valuable role in the treatment of Parkinson's disease.
27例特发性帕金森病患者完成了一项双盲交叉试验,该试验比较了肠溶左旋多巴(Prodopa)与左旋多巴 - 卡比多巴组合制剂(息宁)。使用这两种药物中的任何一种都很容易稳定患者的病情,并且再次观察到肠溶制剂和左旋多巴 - 卡比多巴组合制剂的剂量节省效果。在所使用的剂量下,客观显示左旋多巴 - 卡比多巴组合制剂在71%的受试患者中更有效,尽管当患者比较试验的两个阶段时,对两种制剂并没有明显的个人偏好。两种药物在帕金森病的治疗中都发挥着重要作用。